全文获取类型
收费全文 | 17549篇 |
免费 | 1021篇 |
国内免费 | 140篇 |
专业分类
耳鼻咽喉 | 142篇 |
儿科学 | 434篇 |
妇产科学 | 366篇 |
基础医学 | 1923篇 |
口腔科学 | 510篇 |
临床医学 | 1892篇 |
内科学 | 4071篇 |
皮肤病学 | 225篇 |
神经病学 | 1814篇 |
特种医学 | 507篇 |
外科学 | 2463篇 |
综合类 | 76篇 |
现状与发展 | 1篇 |
一般理论 | 12篇 |
预防医学 | 1314篇 |
眼科学 | 355篇 |
药学 | 963篇 |
中国医学 | 22篇 |
肿瘤学 | 1620篇 |
出版年
2024年 | 14篇 |
2023年 | 143篇 |
2022年 | 291篇 |
2021年 | 555篇 |
2020年 | 315篇 |
2019年 | 517篇 |
2018年 | 553篇 |
2017年 | 452篇 |
2016年 | 433篇 |
2015年 | 513篇 |
2014年 | 755篇 |
2013年 | 932篇 |
2012年 | 1345篇 |
2011年 | 1449篇 |
2010年 | 745篇 |
2009年 | 680篇 |
2008年 | 1242篇 |
2007年 | 1208篇 |
2006年 | 1078篇 |
2005年 | 1074篇 |
2004年 | 1010篇 |
2003年 | 901篇 |
2002年 | 827篇 |
2001年 | 123篇 |
2000年 | 100篇 |
1999年 | 130篇 |
1998年 | 151篇 |
1997年 | 118篇 |
1996年 | 112篇 |
1995年 | 110篇 |
1994年 | 80篇 |
1993年 | 72篇 |
1992年 | 64篇 |
1991年 | 51篇 |
1990年 | 60篇 |
1989年 | 49篇 |
1988年 | 40篇 |
1987年 | 36篇 |
1986年 | 37篇 |
1985年 | 40篇 |
1984年 | 39篇 |
1983年 | 43篇 |
1982年 | 35篇 |
1981年 | 23篇 |
1980年 | 20篇 |
1979年 | 28篇 |
1978年 | 16篇 |
1977年 | 15篇 |
1976年 | 10篇 |
1974年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
191.
Luisa Di Marzio Alfredo Di Leo Benedetta Cinque Donatella Fanini Alessio Agnifili Pasquale Berloco Michele Linsalata Dionigi Lorusso Michele Barone Claudio De Simone Maria Grazia Cifone 《Cancer epidemiology, biomarkers & prevention》2005,14(4):856-862
OBJECTIVES: Intestinal alkaline sphingomyelinase, by exerting a major role in dietary sphingomyelin digestion, is responsible for the generation of messengers able to trigger the rapid turnover and apoptosis in intestinal epithelial cells. Markedly reduced mucosal alkaline sphingomyelinase activity has been associated with human colorectal neoplasms. The aim of this study was to analyze the alkaline sphingomyelinase activity in feces from healthy subjects and colorectal adenocarcinoma patients and to correlate it with the enzyme activity in intestinal tissues. MATERIALS AND METHODS: The enzyme activity was measured both in the intestinal samples from 12 healthy controls and 51 patients with colorectal adenocarcinoma (tumoral and paratumoral tissue) and in the fecal samples of 34 healthy subjects and 29 patients with adenocarcinoma. The relation between sphingomyelinase activity and Dukes' stage, cell differentiation degree, age, and gender was also analyzed. RESULTS: Alkaline sphingomyelinase was significantly decreased (P < 0.001; mean reduction >90%) in tumoral intestinal mucosa of patients compared with controls independently of Dukes' stage and tumor differentiation grade. Interestingly, the enzyme activity in histologically normal paratumoral tissues was statistically lower than control samples (P < 0.001). As occurs in neoplastic tissues, a relevant mean reduction (P < 0.0001; almost 90%) of alkaline sphingomyelinase was revealed in stool samples from tumor patients when compared with controls. CONCLUSION: These findings may have implications for cancer biology and perhaps also for the design of clinical test, thus suggesting that the fecal sphingomyelinase activity could really reflect the human intestinal mucosa enzyme level and could represent a new marker for human colorectal adenocarcinoma, mainly taking into account its early appearance in intestinal neoplasms. 相似文献
192.
Simona Soverini Giovanni Martinelli Gianantonio Rosti Simona Bassi Marilina Amabile Angela Poerio Barbara Giannini Elena Trabacchi Fausto Castagnetti Nicoletta Testoni Simona Luatti Antonio de Vivo Daniela Cilloni Barbara Izzo Milena Fava Elisabetta Abruzzese Daniele Alberti Fabrizio Pane Giuseppe Saglio Michele Baccarani 《Journal of clinical oncology》2005,23(18):4100-4109
PURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML) patients. To shed further light on the frequency, distribution, and prognostic significance of ABL mutations, we retrospectively analyzed a homogeneous cohort of late chronic phase CML patients who showed primary cytogenetic resistance to imatinib. PATIENTS AND METHODS: Using denaturing high-performance liquid chromatography (D-HPLC) and sequencing, we screened for ABL mutations in a total of 178 bone marrow and/or peripheral blood samples from 40 late chronic phase CML patients homogeneously treated with imatinib 400 mg/d, who did not reach a major cytogenetic response at 12 months. RESULTS: Mutations were found in 19 of 40 patients (48%). Mutations were already detectable by D-HPLC at a median of 3 months from the onset of therapy. The presence of a missense mutation was significantly associated with a greater likelihood of subsequent progression to accelerated phase/blast crisis (P = .0002) and shorter survival (P = .001). Patients carrying mutations falling within the P-loop seemed to have a particularly poor outcome in terms of time to progression (P = .032) and survival (P = .045). CONCLUSION: Our results show that, irrespective of the hematologic response, monitoring for emerging mutations in the first months of therapy may play a role in detecting patients with worse prognosis, for whom a revision of the therapeutic strategy should be considered. 相似文献
193.
M Lanciotti C Dufour L Corral P Di Michele S Pigullo G De Rossi G Basso A Leszl M Luciani L Lo Nigro C Micalizzi M G Valsecchi A Biondi R Haupt 《Leukemia》2005,19(2):214-216
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a detoxification enzyme that protects cells against oxidative stress and toxic quinones. A polymorphism (C609T) in the gene produces in the heterozygous individuals (C/T) a reduction and in those homozygous for the variant allele (T/T) the abolishment of NQO1 protein activity. To assess whether NQO1 inactivating polymorphism (CT/TT) was a possible risk factor for infant acute lymphoblastic leukemia (iALL), we investigated the distribution of NQO1 genotype in 50 iALL patients, 32 with MLL gene rearrangements (MLL+) and 18 without (MLL-). As controls, 106 cases of pediatric ALL (pALL), and 147 healthy subjects were also studied. Compared to normal controls, the frequency of the low/null activity NQO1 genotypes was significantly higher in the iALL MLL- (72 vs 38%, P=0.006; odds ratio (OR) 4.22, 95% confidence interval (CI) 1.43-12.49), while no differences were observed in iALL MLL+ (44 vs 38%, P=0.553; OR 1.26, 95% CI 0.58-2.74). Similar results were observed when pALL were used as control. Our results indicate that only the iALL patients without MLL rearrangements had a significantly higher frequency of NQO1 genotypes associated with low/null activity enzyme, suggesting a possible role for NQO1 gene as an MLL-independent risk factor, in the leukemogenic process of this subtype of iALL. 相似文献
194.
Obesity is a multifactorial, chronic disorder that has reached epidemic proportions in most industrialized countries and is threatening to become a global epidemic. Obese patients are at higher risk from coronary artery disease, hypertension, hyperlipidemia, diabetes mellitus, cancers, cerebrovascular accidents, osteoarthritis, restrictive pulmonary disease, and sleep apnoea. In particular, visceral fat accumulation is usually accompanied by insulin resistance or type 2 diabetes mellitus, hypertension, hypertriglyceridemia, high uremic acid levels, low high density lipoprotein (HDL) cholesterol to define a variously named syndrome or metabolic syndrome. Metabolic syndrome is now considered a major cardiovascular risk factor in a large percentage of population in worldwide. Both obesity and metabolic syndrome are particularly challenging clinical conditions to treat because of their complex pathophysiological basis. Indeed, body weight represents the integration of many biological and environmental components and relationships among fat and glucose tolerance or blood pressure are not completely understood. Efforts to develop innovative anti-obesity drugs, with benefits for metabolic syndrome, have been recently intensified. In general two distinct strategies can be adopted: first, to reduce energy intake; second, to increase energy expenditure. Here we review some among the most promising avenues in these two fields of drug therapy of obesity and, consequently, of metabolic syndrome. 相似文献
195.
Filippo Spreafico Michele Murelli Brian W. Timmons Maura Massimino Ronald Barr 《Pediatric blood & cancer》2019,66(8)
The burden of morbidities affecting cardiovascular and musculoskeletal systems, metabolism, and psychosocial health in young patients with cancer is high. It is alarming that patients and survivors of childhood cancer are less physically active than their healthy peers, since exercise may improve many of these conditions significantly and is associated with reduction in all‐cause mortality in the general population. Systematic integration of exercise programing into cancer care remains an exception, above all in children. Pediatric oncologists may contribute to a culture shift towards educating patients and stakeholders on the benefit of exercise and sports for children and adolescents with cancer. 相似文献
196.
197.
198.
Laura Evangelista Anna Rita Cervino Riccardo Sanco Michele Bignotto Tania Saibene Silvia Michieletto Cristina Ghiotto Fernando Bozza Marta Paiusco Giorgio Saladini 《Breast cancer research and treatment》2014,146(2):331-340
The aim of the present study was to assess the feasibility of a portable gamma camera (PGC) for guiding surgical treatment in locally advanced breast cancer (LABC) after neoadjuvant therapy (NT). Since January 2012, a PGC (Sentinella 102, ONCOVISION) has been available in our center. We planned to perform a feasibility monocentric prospective study involving 15–20 patients with LABC for assessing the diagnostic performance of this PGC after NT (Breast Cancer Surgery-S102). Before the surgical treatment and at the end of NT an injection of 99mTc-Sestamibi (100–150 MBq) was made. Conventional scintimmamography (SMM) and Sentinella 102 images were obtained from 18 patients. 10 (55.5 %) patients showed a focal uptake of tracer in the breast or lymph nodes before or after the surgical excision (on histological specimen), while 8 did not. The histological specimen concluded for a complete response to NT in 4 (22.2 %) patients and for a partial or no response to treatment in the remnant 14 subjects. The specificity and false-negative rate of the Sentinella 102 compared to SMM were 100 % for both and 38 % vs. 60 %, respectively. The global diagnostic accuracy of Sentinella 102 was: 66.7 % (95 % confidence interval: 44.88–88.44 %). The present feasibility study shows how a new nuclear imaging device can be useful in the operating theatre for guiding a radical surgery approach in patients with LABC after NT. 相似文献
199.
Elise Caccappolo-van Vliet Michele Miozzo Yaakov Stern 《Cognitive neuropsychology》2013,30(8):820-839
RG, a patient with probable Alzheimer's disease, showed a severe impairment in nonword reading. RG's word reading was intact, for example, as demonstrated by her scores in standardised reading tasks, which were comparable to those of normal controls. No phonological impairment was apparent in speech production and comprehension. Moreover, RG performed well in a series of phonological tasks (e.g., production of a rhyming word, phoneme identification) on which patients with a reading deficit selective for nonwords have been reported to encounter problems. RG's data severely constrain reading models proposing that nonword reading deficits are caused by phonological deficits. However, RG's data are compatible with dual-route reading models, which do not propose a link between nonword reading deficits and phonological impairment. 相似文献
200.